 |  |  |
|---|
Pneumococcal Vaccine Candidate MVX01
A pneumolysin protein fused with Choline binding protein A epitopes creates our serotype-independent, dual-antigen vaccine to combat pneumococcal disease
C. difficile Vaccine Candidate MVX02
C. difficile infections result in 14,000 deaths per year in the United States. Matrivax is targeting both the pathogen and the toxoids in our unique vaccine.
Applying breakthrough science to develop innovative, clinically-impactful vaccines for people in need around the world
1. WHO, 2000; 2. WHO, 2005; 3. CDC, 2019